Novo nordisk (nvo) faces securities class action after weight loss therapy trial data disappoints, analyst questions trial's design - hagens berman

Nvo investors with losses encouraged to contact the firm san francisco, ca / access newswire / january 29, 2025 / novo nordisk a/s (nyse:nvo) is facing a class-action lawsuit from investors who allege the pharmaceutical giant misled them about the prospects of its experimental obesity drug, cagrisema. hagens berman urges investors who purchased novo nordisk shares and suffered substantial losses to submit your losses now.
NVO Ratings Summary
NVO Quant Ranking